IT 9302
Latest Information Update: 08 Sep 2006
At a glance
- Originator Amersham
- Class Anti-inflammatories
- Mechanism of Action Interleukin 10 stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Pancreatitis
Most Recent Events
- 08 Sep 2006 Discontinued - Preclinical for Pancreatitis (unspecified route)
- 02 Dec 2003 No development reported - Preclinical for Pancreatitis (unspecified route)
- 19 May 2000 Preclinical development for Pancreatitis (Unknown route)